<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03391128</url>
  </required_header>
  <id_info>
    <org_study_id>P3NPhemodialysis</org_study_id>
    <nct_id>NCT03391128</nct_id>
  </id_info>
  <brief_title>Circulating P3NP and Cardiovascular Events in Hemodialysis Patients</brief_title>
  <official_title>Involvement of Circulating Aminoterminal Propeptide of Type 3 Procollagen in Cardiovascular Events in Patients on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Toujinkai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Toujinkai Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether circulating levels of aminoterminal propeptide of type III
      procollagen (PIIINP) can predict the cardiovascular events in hemodialysis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type III collagen abundantly exists in the cardiovascular system including the aorta and
      heart. The aminoterminal propeptide of type III procollagen (PIIINP) is an extension peptide
      of type III procollagen, which is cleaved off stoichiometrically during conversion from type
      III procollagen to type III collagen and liberated to serum. Elevated serum concentrations of
      PIIINP are considered a marker of higher collagen turnover and tissue fibrosis including the
      heart and vascular system. In this study, the investigators prospectively examined whether
      serum levels of PIIINP could be a biomarker for predicting cardiovascular events in
      hemodialysis patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2005</start_date>
  <completion_date type="Actual">January 31, 2005</completion_date>
  <primary_completion_date type="Actual">January 31, 2005</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>January 1, 2005 to January 31, 2011</time_frame>
    <description>Cardiac deaths, non-fatal acute myocardial infarction, obstructive coronary artery disease needing intervention, vasospastic angina identified by angiography, heart failure needing hospitalization, bradycardia needing pacemaker implantation, dissecting aortic aneurysm, cardiac valvular disease needing valve replacement, peripheral artery disease needing bypass surgery or leg amputation.</description>
  </primary_outcome>
  <enrollment type="Actual">244</enrollment>
  <condition>Cardiovascular Events</condition>
  <condition>Cardiac Fibrosis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample for measurement of serum P3NP concentration.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Of 302 patients who met the inclusion criteria, 58 patients were excluded based on the
        exclusion criteria. Consequently, 244 patients (126 men and 118 women; mean age, 64 ± 11
        years; dialysis duration, 11.5 ± 7.8 years) were enrolled in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  End-stage kidney disease patients who had been undergoing maintenance hemodialysis
             over one year in Toujinkai Hospital at the point of January 1, 2005

        Exclusion Criteria:

          -  Histories of coronary events and/or interventions

          -  Congestive heart failure of New York Heart Association grades III to IV

          -  Moderate or worse valvular heart disease

          -  Permanent pacemaker implantation

          -  Idiopathic cardiomyopathy

          -  Chronic obstructive pulmonary disease

          -  Malignancy

          -  Acute hepatitis, chronic hepatitis, or liver cirrhosis including carrier of hepatitis
             virus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masato Nishimura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tojinkai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toujinkai Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>612-8026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2017</study_first_submitted>
  <study_first_submitted_qc>January 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2018</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Toujinkai Hospital</investigator_affiliation>
    <investigator_full_name>Masato Nishimura, MD</investigator_full_name>
    <investigator_title>Director of Cardiovascular division</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

